反応式
C[N:2]1CCN(C2C=CC(NC3C4[N:17]([N:29]=[CH:30]N=4)[C:18]([C:21]4C=C(C(N)=O)SC=4)=CN=3)=CC=2)CC1.Br[C:33]1[N:38]2[N:39]=[CH:40][N:41]=[C:37]2[C:36]([NH:42][C:43]2[CH:44]=[CH:45][C:46]([N:52]3[CH2:57][CH2:56][O:55][CH2:54][CH2:53]3)=[C:47]([CH:51]=2)[C:48]([NH2:50])=[O:49])=[N:35][CH:34]=1.CC1(C)C(C)(C)OB(C2C=NNC=2)O1>C([O-])([O-])=O.[K+].[K+].O1CCOCC1.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[NH3:2].[NH:17]1[CH:18]=[C:21]([C:33]2[N:38]3[N:39]=[CH:40][N:41]=[C:37]3[C:36]([NH:42][C:43]3[CH:44]=[CH:45][C:46]([N:52]4[CH2:53][CH2:54][O:55][CH2:56][CH2:57]4)=[C:47]([CH:51]=3)[C:48]([NH2:50])=[O:49])=[N:35][CH:34]=2)[CH:30]=[N:29]1参加物
反応物 3
生成物 2
試薬・触媒・溶媒 3
実験手順
This compound may be prepared using methods as described for Compound 6, step 4 using 5-(5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamino)-2-morpholin-4-yl-benzamide (140 mg, 0.33 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (130 mg, 0.67 mmol) and Pd(PPh3)4 (96 mg, 0.083 mmol) in 1.5M K2CO3 (aq) (1.93 mL) and dioxane (3.44 mL). The crude material is purified by silica gel column chromatography eluting with DCM followed by 99:1 then 97:3 then 95:5 DCM:NH3 (7M in MeOH) to afford the title compound as a white solid (40.5 mg, 30%). 1H-NMR (400 MHz, d6-DMSO) δ(ppm) 2.96 (4H, m), 3.79 (4H, m), 7.28 (2H, d), 7.45 (1H, m), 7.54 (1H, br s), 8.01-8.09 (1H, dd), 8.25 (1H, s), 8.50 (1H, d), 8.69 (1H, br s), 8.78 (1H, s), 9.98 (1H, s), 13.3 (1H, br s). LCMS: Rt 2.23 min (96.9%), m/z (APCI) 406 (M+H)+.
後処理
- customThis compound may be prepared
- customThe crude material is purified by silica gel column chromatography
- washeluting with DCM
出典と根拠
- ORDレコード
- ord-6c6efd22323b4263a477df3bd1120f0d
- 出典データセット
- uspto-grants-2009_03
- 特許番号
- US07501411B2
関連ノート
読み込み中…